Filing Flows › Lifecore Biomedical (LFCR) › Q3 FY26
Lifecore Biomedical (LFCR) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed May 6, 2026
Lifecore Biomedical (LFCR) reported revenue of $23.2M for the third quarter fiscal 2026 (Q3 FY26). Operating margin was -20.1%, net loss $15.0M (64.6% of revenue).
Lifecore Biomedical, Q3 FY26: revenue $23.2M, operating margin -20.1%, net loss $15.0M, operating cash flow $4.7M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.2M | — | — |
| Operating profit | −$4.7M | — | — |
| Net earnings | −$15.0M | — | — |
| Operating cash flow | $4.7M | — | — |
| Free cash flow | $3.6M | — | — |
What changed
Revenue was $23.2M in Q3 FY26. CDMO was the largest line at 68% of revenue.
Gross margin was 19.2%. Operating costs exceeded revenue by $4.7M, an operating margin of -20.1%. The quarter ended with a net loss of $15.0M. Net interest and other expense of $10.3M was the main reason.
Operating cash flow was $4.7M. Non-cash charges added back $2.3M of depreciation and $1.7M of share-based compensation. Working capital and other items added $15.7M. Capital expenditures of $1.1M left free cash flow of $3.6M.
Questions
What was Lifecore Biomedical's revenue in the third quarter fiscal 2026?
Lifecore Biomedical (LFCR) reported revenue of $23.2M for the third quarter fiscal 2026 (Q3 FY26).
Was Lifecore Biomedical profitable in the third quarter fiscal 2026?
Operating loss was $4.7M (-20.1% of revenue) and net loss $15.0M.